trending Market Intelligence /marketintelligence/en/news-insights/trending/4IhSwQS2MwWJc1f9P0UUlg2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

GSK's president of US pharmaceuticals to step down; replacement named

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform

GSK's president of US pharmaceuticals to step down; replacement named

GlaxoSmithKline PLC said Jack Bailey is stepping down as president of U.S. pharmaceuticals at the end of 2019.

Bailey, who has been with GlaxoSmithKline since 2009, will remain as a consultant to the company on the U.S. external environment until 2020.

Meanwhile, the company named Maya Martinez-Davis as Bailey's successor. Martinez-Davis is currently the regional president of EMD Serono Inc.'s Latin America region.

EMD Serono is the Rockland, Mass.-based biopharmaceutical unit of Germany's MERCK KGaA which develops therapies for cancer and neurodegenerative diseases.

Martinez-Davis is set to join GlaxoSmithKline in mid-September and will begin her responsibility as head of the company's U.S. pharmaceuticals business beginning Jan. 1, 2020.